Evidence map›Paper›PMID 40399368›Full record

ArticleScientific reports2025

IL-15-Activated CD38

Ke Liu, Hongliang Dong, Kaiyue Zhang, Wanping Yan, Huanyu Wu, Jing Fan, Wei Ye

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. IL-15/NKG2D signaling-mediated activation of CD8Journal of thoracic disease · 2026
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ke LiuDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Hongliang DongDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Kaiyue ZhangDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Wanping YanDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Huanyu WuDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Jing FanDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China. fanjing@njucm.edu.cn.
Wei YeDepartment of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China. yewei@njucm.edu.cn.

Funding

Nanjing Infectious Disease Clinical Medical Center, Innovation center for infectious disease of Jiangsu Province No. CXZX202232the Medical Science and Technology Development Foundation, Nanjing Department of Health YKK21119the Scientific research project of Jiangsu Provincial Health Commission M2021074the Talent Support Program of the Second Hospital of Nanjing RCMS23001
6 · The paper itself

Abstract

The development and progression of liver cirrhosis are considerably influenced by immune processes, with CD8 + T cells playing a key role. Notably, cytokines can activate bystander CD38 + HLA-DR + CD8 + T cells without the need for T cell receptor (TCR) stimulation. However, their role in liver fibrosis remains controversial. This study aimed to investigate the pathological role of CD38 + HLA-DR + CD8 + T cells in cirrhosis progression and explore the mechanisms that regulate their functions. Peripheral blood mononuclear cells (PBMCs) were extracted from patients with cirrhosis and healthy donors, and the ratio of CD38

Indexed as

CD8-Positive T-LymphocytesInterleukin-15Liver CirrhosisADP-ribosyl Cyclase 1AdultFemaleHLA-DR AntigensHumansJanus KinasesLymphocyte ActivationMaleMembrane GlycoproteinsMiddle AgedPhosphatidylinositol 3-KinasesSignal TransductionSTAT5 Transcription FactorADP-ribosyl Cyclase 1CD38 protein, humanHLA-DR AntigensIL15 protein, humanInterleukin-15Janus KinasesMembrane GlycoproteinsMTOR protein, humanPhosphatidylinositol 3-KinasesSTAT5 Transcription FactorTOR Serine-Threonine KinasesBystander activationCD8+ T cellIL-15Liver cirrhosisTCR

Identifiers

PMID40399368
PMCPMC12095495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.